PAP
LBRX icon

Persistent Asset Partners’s LB Pharmaceuticals LBRX Stock Holding History

Persistent Asset Partners’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160K Buy
+4,926
New +$145K 0.05% 243
2026
Q1 		– Sell
-4,080
Closed -$90.8K – 507
2025
Q4 		$90.8K Buy
+4,080
New +$71.3K 0.04% 275

Other funds holding LBRX

Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Trails Edge Capital Partners
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Commodore Capital
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Persistent Asset Partners's LBRX Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in LB Pharmaceuticals (LBRX) in Q2 2026: 4,926 shares worth $160K. The stake represents 0.05% of the portfolio and ranks #243 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in LBRX as recently as Q4 2025.

Persistent Asset Partners first reported a position in LBRX in Q4 2025 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Persistent Asset Partners held 4,926 shares of LB Pharmaceuticals worth $160K as of Q2 2026.
  • LB Pharmaceuticals was a new Persistent Asset Partners position in Q2 2026.
  • LB Pharmaceuticals made up 0.05% of Persistent Asset Partners's portfolio in Q2 2026, its #243 holding.
  • Persistent Asset Partners first reported a position in LB Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.